Fairvalue-Calculator Fairvalue-Calculator
EN DE

SMO ClinPlus CO.,LTD. (301257) Fair Value & Analysis

Healthcare · CN · Market cap 3.2B CNY

Price¥40.65
Fair Value¥29.26
Upside-28.0%
Quality95/100
Evidence: High Range ¥17.77 – ¥38.16

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

SMO ClinPlus CO.,LTD. (301257) currently trades at ¥40.65, while our model-based Fair Value estimate is ¥29.26 — implying the stock looks roughly 28.0% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

SMO ClinPlus CO.,LTD. provides site management services in research development in pharmaceuticals, medical devices, and health-related products in China. The company offers early modeling, preliminary preparation plan trial site initiation, on-site execution, and project management services. SMO ClinPlus CO.,LTD. was founded in 2009 and is based in Shanghai, China.

Open the full interactive analysis →

Similar stocks

Thermo Fisher Scientific Inc (TMO) -96% Danaher Corporation (DHR) -52% WuXi AppTec Co (WUXAY) +35% IDEXX Laboratories, Inc (IDXX) -66% Lonza Group (LZAGY) -59% Agilent Technologies, Inc (A) -54%

Frequently asked questions

Is SMO ClinPlus CO.,LTD. (301257) undervalued?
As of Jun 24, 2026, our model estimates a fair value of ¥29.26 versus a price of ¥40.65 — about −28% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 301257?
Our 21-model fair value for SMO ClinPlus CO.,LTD. is ¥29.26 (as of Jun 24, 2026), built from audited fundamentals. The current price is ¥40.65.
What is the quality score of 301257?
SMO ClinPlus CO.,LTD. has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.